Biotech Platform Architecture · Early-stage Biotech · London
The most consequential decisions in platform biotech live at the joints — between the science, IP strategy, and the commercial position
Photon Fusion advises founders and executives who want an adviser fluent in all three - not three separate opinions stitched together afterward.
Twenty years across the bench, the patent, and the commercial decision
I am Dr Michal Legiewicz, founder and Principal Scientific Advisor of Photon Fusion Ltd. The practice was built around a pattern I observed repeatedly across two decades in nucleic acid science: the most consequential failures in platform biotechnology rarely come from poor science or poor strategy in isolation. They arise at the interfaces between technical design, IP architecture, and commercial positioning — interfaces that are typically no one's explicit responsibility.
My career has followed those interfaces. Bench research at the NIH and Yale; platform development at the University of Warwick and in UK biotech; inventor-level patent work on nucleic acid constructs. The common thread is working where technical, legal, and commercial decisions interact, and where platform value is either compounded or quietly eroded as a result.
Photon Fusion exists because the advice available to early-stage biotech is structurally siloed. Scientists advise on science. Patent attorneys advise on patents. Business consultants advise on commercial strategy. The failure modes that most reliably kill platforms — compounding unpredictability and path foreclosure — live at the interfaces between these disciplines, and identifying them requires fluency in all three.
I work directly with founders, CSOs, and investors who want an adviser who can read molecular biology at first principles, interpret a patent claim with practitioner-level understanding, and assess whether the resulting platform constitutes durable competitive advantage or accumulated hidden debt.
One domain. Practised at depth, monitored at the frontier.
My core expertise embraces nucleic acid biochemistry and biology, and its platform applications. This spans gene synthesis and vector design, gene editing and targeted delivery, DNA and mRNA therapeutics, and the emerging frontier where nucleic acid value is migrating next. Some of these areas I practise directly; others I monitor continuously because they shape the IP and commercial landscape in which my clients operate. The distinction matters, and the sections below make it explicit.
Core domain — DNA technology
Gene design and synthesis, expression systems, construct engineering for manufacturability, and full-stack architecture of synthetic and enzymatic DNA platforms. The foundational layer on which all downstream applications depend, and where architectural decisions quietly determine what remains possible at manufacturing scale.
Applied depth — Therapeutics
AAV vector design and non-viral targeted delivery platforms — the domain in which I have contributed directly as a researcher and named inventor. Platform decisions at this layer cascade into manufacturing, IP, and regulatory requirements, which is why the three-lens reading is most consequential here.
Applied depth — Aptamers
Nucleic acid aptamer selection (SELEX), structural characterisation, and applications. A field where novel molecular structure intersects with IP opportunities and commercial territory that remain genuinely underexplored.
Active monitoring — Nanotechnology
DNA and RNA nanotechnology, programmable nanostructures, and nucleic acid-based materials. Emerging platforms in which early IP and architectural decisions set long-term positioning.
Active monitoring — Frontier domains
DNA data storage, and molecular computing. Fields I track continuously because they indicate where nucleic acid IP and platform value are migrating next, even where they are not yet where I practise.
Three lenses. One reading.
The three lenses are not three separate reviews. They are three dimensions of attention held against the same platform — technical design, IP position, and commercial edge — and the substantive work is identifying where they diverge.
The result is not a thicker report. It is a clearer picture of where the platform stands, what is at risk, and where optionality exists.
Technical Lens
Where does the science hold at molecular resolution, and where does it rest on assumptions unlikely to survive scale-up, a cell-line swap, or a regulatory question? This reading operates at the level of the bench, and it quietly sets the boundaries within which the other two lenses can see.
IP Lens
Patent landscape assessment, freedom-to-operate analysis, and strategic positioning — evaluated for how IP decisions interact with technical choices and commercial positioning.
Commercial Lens
A differentiation claim that the science cannot carry, or that the IP does not defend, will not survive diligence. The commercial reading is where the technical and IP positions are stress-tested against the narrative on which the next funding round depends.
Three ways to engage
I work across three tiers of engagement, calibrated to what each stage of company building demands. Whether you need scientific input or strategic counsel at the founder level, the through-line is the same: integrated thinking that prevents hidden risk from compounding.
Scientific & Technology Input
Technical choices at the bench — vector design, expression systems, synthesis workflows — quietly constrain what becomes patentable and what reaches market. I work at this level to ensure design decisions don't foreclose strategic options downstream.
IP & Platform Strategy
IP risk compounds across domains. A construct design narrows freedom to operate. A filing gap exposes a manufacturing route. I map these cross-domain dependencies — technology, IP, commercial — to see where risk is accumulating before it locks in.
Founder & Investor Advisory
At inflection points — fundraising, licensing, pivots — the full picture matters: where the science stands, what the IP actually protects, and whether the commercial narrative survives diligence. I stress-test these alignments before capital decisions lock them in.
Built for
Three ways to work together
Engagements are structured to match the depth and continuity that each mandate requires. From embedded fractional leadership to discrete advisory sessions, the through-line is the same: substantive thinking that produces something worth having.
CTO / CSO — embedded advisory
The deepest form of engagement. Photon Fusion Principal Advisor holds a defined fractional role — typically CTO or CSO — within the client's leadership structure, operating at approximately 20% of working time. This is not a consultancy arrangement wearing an operational title: it is a genuine strategic presence, with the access and continuity that genuine presence requires.
Platform understanding is built iteratively. By month three, the advisor knows the technology well enough to have opinions that matter — on IP architecture, platform positioning, investor narrative, and where the scientific programme and the commercial strategy are in tension.
Defined scope · defined deliverable
A bounded engagement with a specific objective and a written deliverable. Typical projects include IP landscape review and whitespace mapping, platform technical assessment, competitive intelligence synthesis, or preparation for a fundraise or licensing discussion.
Scope is defined in a Statement of Work before commencement. Requests outside that scope are identified as such and quoted separately — not absorbed silently. The deliverable is written and stands on its own: not a presentation designed to generate the next meeting, but a document designed to be used.
Discrete · as-needed
One-off advisory sessions, expert calls, due diligence reviews, or advisory board participation. No fixed term, no operational involvement. Minimum booking of half a day ensures that any session produces something worth having rather than an introductory conversation dressed as advice.
This tier is also the natural entry point for a relationship that may evolve. Many Tier 1 and Tier 2 engagements begin with a Tier 3 conversation — a chance to assess fit before either party commits to something deeper.
Writing on platforms, risk, and decision-making
Selected essays from the Photon Fusion Substack, examining the structural challenges of building platform biotechnology and the frameworks for navigating them.
Cross-domain look: the mechanisms that kill biotech platforms hide at the joints, not the steel
Photon Fusion · Substack 02Be Greedy When Others Are Fearful — In Biotech, Not Just Stocks
Photon Fusion · Substack 03The Board You Cannot See: Synthetic Terrain Mapping Circuit for Biotech Strategy
Photon Fusion · SubstackBegin the conversation
Photon Fusion engages selectively, prioritising mandates where integrated scientific and strategic perspective can have the most decisive impact. If you are building a biotechnology platform and approaching decisions at which the scientific, IP, and commercial dimensions intersect, I would welcome hearing from you.